Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Davidson

Showing results (281-290 of 358) with videos related to

Pageof 36
Sort By:
Schizophrenia Bulletin|March 31, 2023
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE StudyLinda Levi, Mor Bar-Haim, Inge Winter-van Rossum, et al.
The American Journal of Psychiatry|May 3, 2005
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trialNina Schooler, Jonathan Rabinowitz, Michael Davidson, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
Neuroscience Applied|June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurementArmida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
The American Journal of Psychiatry|July 14, 2021
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans AffairsMark Weiser, John M Davis, Clayton H Brown, et al.
JMIR Research Protocols|May 18, 2026
Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational StudyDan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, et al.
Archives of General Psychiatry|September 6, 2006
Advancing paternal age and autismAbraham Reichenberg, Raz Gross, Mark Weiser, et al.
Clinical Colorectal Cancer|July 8, 2018
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 PatientsMichael Davidson, Catherine Cafferkey, Emily Frances Goode, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
Comprehensive Psychiatry|February 17, 2005
Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-LMark Weiser, Kyra Kanyas, Dolores Malaspina, et al.
Pageof 36

Showing results (281-290 of 358) with videos related to

Sort By:
Pageof 36
Schizophrenia Bulletin|March 31, 2023
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE StudyLinda Levi, Mor Bar-Haim, Inge Winter-van Rossum, et al.
The American Journal of Psychiatry|May 3, 2005
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trialNina Schooler, Jonathan Rabinowitz, Michael Davidson, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
Neuroscience Applied|June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurementArmida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
The American Journal of Psychiatry|July 14, 2021
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans AffairsMark Weiser, John M Davis, Clayton H Brown, et al.
JMIR Research Protocols|May 18, 2026
Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational StudyDan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, et al.
Archives of General Psychiatry|September 6, 2006
Advancing paternal age and autismAbraham Reichenberg, Raz Gross, Mark Weiser, et al.
Clinical Colorectal Cancer|July 8, 2018
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 PatientsMichael Davidson, Catherine Cafferkey, Emily Frances Goode, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
Comprehensive Psychiatry|February 17, 2005
Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-LMark Weiser, Kyra Kanyas, Dolores Malaspina, et al.
Pageof 36